ARKgen BioScions
PrivateLast Round
Series A
Jul 13, 2026
Total Funding Raised
$9.5M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
ARKgen BioScions operates in Healthcare & Life Sciences and is based in Daejeon. Its latest recorded funding round was a Series A round in July 2026.
ARKgen BioScions is a biotechnology company that develops multispecific antibody-based immuno-oncology therapeutics using its proprietary AMB platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ARKgen BioScions Comparables
Compare ARKgen BioScions with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| De Novo Biotherapeutics | 81% | |
| Invenra | 81% | |
| Numab Therapeutics | 78% |
For institutional investors. Book with your work email.
ARKgen BioScions Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
ARKgen BioScions Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Woori Venture Partners Co., Ltd. | Series A |
| IBK Venture Investment | Series A |
| ScaleUp Partners | Series A |
| IMM Investment | Series A |
| Korea Credit Guarantee Fund | Series A |
| Industrial Bank of Korea | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 13, 2026
$7M round with participation from IBK Venture Investment and IMM Investment.
- Dec 1, 2023
$3M raised in Pre Seed round.
For institutional investors. Book with your work email.
ARKgen BioScions Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ARKgen BioScions's valuation, stock price, and market status.
Is ARKgen BioScions a public or private company?
ARKgen BioScions is a private company.
What is the current stock price of ARKgen BioScions?
ARKgen BioScions is a private company, so its shares have no public market price. Caplight tracks ARKgen BioScions's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ARKgen BioScions worth (valuation)?
Valuation information for ARKgen BioScions is not publicly available.
Can I buy ARKgen BioScions stock?
ARKgen BioScions shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ARKgen BioScions's last funding round?
ARKgen BioScions's most recent funding round was Series A on July 13, 2026.
Who are the main investors in ARKgen BioScions?
Key investors in ARKgen BioScions include Woori Venture Partners Co., Ltd., IBK Venture Investment, ScaleUp Partners, IMM Investment, Korea Credit Guarantee Fund.
Will ARKgen BioScions IPO soon?
No public IPO plans have been announced for ARKgen BioScions.
How can I track ARKgen BioScions secondary market activity?
Caplight tracks bids, offers, and trades in ARKgen BioScions's shares on secondary markets.